Title : Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Pub. Date : 2010 Aug

PMID : 20653359






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Evidence demonstrates that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy (i.e., atorvastatin and rosuvastatin) significantly reduces surrogate cardiovascular markers, particularly LDL, in patients with ESRD requiring hemodialysis; however, no statin has proved to reduce cardiovascular morbidity or mortality in this population. Rosuvastatin Calcium 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens